Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

DESCRIPTION Update of the 2008 U.S. Preventive Services Task Force (USPSTF) recommendation statement on screening for prostate cancer. METHODS The USPSTF reviewed new evidence on the benefits and harms of prostate-specific antigen (PSA)-based screening for prostate cancer, as well as the benefits and harms of treatment of localized prostate cancer. RECOMMENDATION The USPSTF recommends against PSA-based screening for prostate cancer (grade D recommendation).This recommendation applies to men in the general U.S. population, regardless of age. This recommendation does not include the use of the PSA test for surveillance after diagnosis or treatment of prostate cancer; the use of the PSA test for this indication is outside the scope of the USPSTF.

[1]  Martin Fortin,et al.  Canadian Task Force on Preventive Health Care , 2012 .

[2]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[3]  Hans Garmo,et al.  Radical prostatectomy or watchful waiting in early prostate cancer. , 2014, The New England journal of medicine.

[4]  P. Fransson,et al.  Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer , 2009, Scandinavian journal of urology and nephrology.

[5]  Kathleen N Lohr,et al.  Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[6]  Peter H Gann,et al.  Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.

[7]  Michael M Lieber,et al.  Journal Review , 2003, International Society of Hair Restoration Surgery.

[8]  A. Miller New data on prostate-cancer mortality after PSA screening. , 2012, The New England journal of medicine.

[9]  H. Dubben Trials of prostate-cancer screening are not worthwhile. , 2009, The Lancet. Oncology.

[10]  G. Haas,et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.

[11]  C. Newschaffer,et al.  Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. , 2000, Journal of the National Cancer Institute.

[12]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[13]  T. Wilt,et al.  The prostate cancer intervention versus observation trial , 1994 .

[14]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[15]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[16]  Associations of lower urinary tract symptoms with prostate‐specific antigen levels, and screen‐detected localized and advanced prostate cancer: a case‐control study nested within the UK population‐based ProtecT (Prostate testing for cancer and Treatment) study , 2008, BJU international.

[17]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[18]  F. Hamdy,et al.  Measuring the psychosocial impact of population‐based prostate‐specific antigen testing for prostate cancer in the UK , 2006, BJU international.

[19]  F. Labrie,et al.  Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial , 2004, The Prostate.

[20]  L. Holmberg,et al.  Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. , 2011, The Lancet. Oncology.

[21]  Peter C Albertsen,et al.  Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. , 2009, Journal of the National Cancer Institute.

[22]  T. Tammela,et al.  Prostate cancer mortality in the Finnish randomized screening trial. , 2013, Journal of the National Cancer Institute.

[23]  T. Wilt The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer. , 2012, Journal of the National Cancer Institute. Monographs.

[24]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[25]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[26]  Dirk F Moore,et al.  Survival following primary androgen deprivation therapy among men with localized prostate cancer. , 2008, JAMA.

[27]  P. Corso,et al.  National Institutes of Health State-of-the-Science Conference , 2012 .

[28]  Lisa M. Schwartz,et al.  Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. , 2005, Journal of the National Cancer Institute.

[29]  D. Bates,et al.  Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. , 2004, The American journal of medicine.

[30]  H. Welch,et al.  Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.

[31]  Rascon [The National Cancer Institute]. , 1953, Boletin cultural e informativo - Consejo General de Colegios Medicos de Espana.

[32]  A. Vickers,et al.  Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Gohagan,et al.  Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening , 2009, The Annals of Family Medicine.

[34]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[35]  T. Stukel,et al.  Changing patterns in competing causes of death in men with prostate cancer: a population based study. , 2004, The Journal of urology.

[36]  S. Lipsitz,et al.  Comparative effectiveness of minimally invasive vs open radical prostatectomy. , 2009, JAMA.

[37]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[38]  M. Roobol,et al.  Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. , 2007, Journal of the National Cancer Institute.

[39]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[40]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[41]  U. Norming,et al.  15-year followup of a population based prostate cancer screening study. , 2009, The Journal of urology.

[42]  D. Bates,et al.  The impact of a suspicious prostate biopsy on patients’ psychological, socio-behavioral, and medical care outcomes , 2006, Journal of General Internal Medicine.

[43]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  T. Wilt,et al.  Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer , 2008, Annals of Internal Medicine.

[45]  F. Hamdy,et al.  Population‐based prostate‐specific antigen testing in the UK leads to a stage migration of prostate cancer , 2009, BJU international.

[46]  T. Gomes,et al.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. , 2012 .

[47]  J. Kovář,et al.  Calcium and magnesium infusions for prevention of oxaliplatin-induced peripheral neuropathy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[49]  J. Hugosson,et al.  Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. , 2007, European urology.

[50]  A. D'Amico,et al.  Comorbidity and mortality results from a randomized prostate cancer screening trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Therese Miller,et al.  Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[52]  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.

[53]  Anssi Auvinen,et al.  Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2012, European urology.

[54]  T. Tammela,et al.  False-positive screening results in the Finnish prostate cancer screening trial , 2010, British Journal of Cancer.

[55]  S. Freedland,et al.  Five-year downstream outcomes following prostate-specific antigen screening in older men. , 2013, JAMA internal medicine.

[56]  Mohammad Hassan Murad,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[57]  Andrew J Vickers,et al.  An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. , 2011, Journal of the National Cancer Institute.

[58]  A. Chokkalingam,et al.  Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.

[59]  P. Keegan,et al.  The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. , 2011, The New England journal of medicine.

[60]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[61]  Jim C Hu,et al.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. , 2011, JAMA.

[62]  T. Tammela,et al.  False-positive screening results in the European randomized study of screening for prostate cancer. , 2011, European journal of cancer.

[63]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[64]  Christina Bougatsos,et al.  Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.

[65]  F. Hamdy,et al.  The ProtecT trial: evaluating the effectiveness of treatments for clinically localised prostate cancer , 2009 .

[66]  T. Wilt,et al.  Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer , 2008 .

[67]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[68]  Christina Bougatsos,et al.  Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation , 2011 .

[69]  Comparative Effectiveness of Minimally Invasive vs Open Radical Prostatectomy , 2010 .

[70]  H Ballentine Carter,et al.  Complications after prostate biopsy: data from SEER-Medicare. , 2011, The Journal of urology.

[71]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[72]  H. Koenig,et al.  Prostate-Specific Antigen-Based Screening for Prostate Cancer , 2011 .

[73]  K. Sherin,et al.  Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. , 2008, American journal of preventive medicine.

[74]  D. Corle,et al.  Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. , 1995, Scandinavian journal of urology and nephrology. Supplementum.

[75]  E. Steyerberg,et al.  The effect of study arm on prostate cancer treatment in the large screening trial ERSPC , 2010, International journal of cancer.

[76]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[77]  Timothy J Wilt,et al.  Prevention and early detection of prostate cancer. , 2014, The Lancet. Oncology.

[78]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[79]  Gerhard Jentzsch,et al.  Working group on , 1991 .

[80]  M. Tonelli,et al.  Recommendations on screening for prostate cancer with the prostate-specific antigen test , 2014, Canadian Medical Association Journal.

[81]  O. Löfman,et al.  Randomised prostate cancer screening trial: 20 year follow-up , 2011, BMJ : British Medical Journal.

[82]  P. Walsh,et al.  Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. , 2003, Journal of Urology.

[83]  Chris Metcalfe,et al.  Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study , 2012, BMJ : British Medical Journal.

[84]  P. Corso,et al.  National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Management of Men With Localized Prostate Cancer , 2012, Annals of Internal Medicine.

[85]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[86]  P. Prorok,et al.  Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial , 2010, Clinical trials.

[87]  L. Schwartz,et al.  The benefits and harms of mammography screening: understanding the trade-offs. , 2010, JAMA.

[88]  T. Wilt,et al.  The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. , 2009, Contemporary clinical trials.

[89]  B. Levin,et al.  American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.

[90]  Douglas K Owens,et al.  Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians , 2013, Annals of Internal Medicine.

[91]  T. Wilt,et al.  Screening for prostate cancer. , 2013, The Cochrane database of systematic reviews.

[92]  D. Katz,et al.  Health perceptions in patients who undergo screening and workup for prostate cancer. , 2007, Urology.